Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Sponsor
Sanofi
Study ID
NCT03992417
Status
Active Not Recruiting

Conditions

  • Dermatitis Atopic

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants

Key Dates

Start date
Jun 11, 2019
Status verified
Jul 2025
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
955 participants (actual)

Arms

  • Arm: Participants with AD
    Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician

Primary Outcome Measure

Baseline Characteristics: Medical history [ Time Frame: Baseline to Month 60 ]

Related Studies